AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06074783 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Allogeneic Bone-Marrow (BM) -Derived Mesenchymal Stromal Cells (MSCs) Product (StromaForte)
Description: 50 x 106 allogeneic BM-derived MSCs formulated in 4 ml infusion solution of sodium chloride supplemented with human serum albumin to be given locally under state of the art way of application that is ultrasound guidance which will ensure precise delivery of the BM derived MSCs at the site of injury or degeneration along with or without 100 x 106 allogeneic BM-derived MSCs formulated in sodium chloride supplemented with human serum albumin to be given via slow intravenous infusion in approximately 30 min. Systemic treatment alone is used when local injection at site of injury or degeneration is not feasible.
Study NCT06544096 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: intervention group (WeChat platform + healthcare)
Description: When the parturients are discharged from the hospital, the medical staff of the intervention group will give the parturient health education about the discharge of the newborn, and the content of the education is the same as that of the control group. At the same time, the medical staff of the intervention group will introduce the usage and functions of the neonatal home skin care management system under the service of WeChat platform+health care to the parturient, and the system regularly pushes home care measures for common skin problems of newborns to their parents in different periods according to their birth dates.
Study NCT06544096 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: control group (routine health education)
Description: When the parturient is discharged from the hospital, the medical staff of the control unit will give the parturient health education about the discharge of the newborn. The contents of the education include neonatal jaundice, umbilical care, vaccination, 42-day follow-up, breastfeeding and so on, which are not included in the system.
Study NCT05896670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: licaminlimab
Description: ophthalmic solution 60 mg/mL Subjects will receive licaminlimab eye drops TID for 6 weeks. All subjects will be assigned artificial tears TID for 2 weeks.
Study NCT05896670 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: vehicle of OCS-02
Description: inert ophthalmic solution vehicle of OCS-02 Subjects will receive vehicle eye drops TID for 6 weeks. All subjects will be assigned artificial tears TID for 2 weeks.
Study NCT06618794 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Recovery Legal Care
Description: These patients will receive support from our HVIP standard of care (Violence Recovery Program) plus our Medical Legal Partnership (Recovery Legal Care) for additional legal support to address health-harming legal needs and public benefits.
Study NCT06618794 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HVIP Standard of Care
Description: These patients will receive HVIP standard of care (Violence Recovery Program Support)
Study NCT06618794 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HVIP Standard of Care
Description: These patients will receive HVIP standard of care (Violence Recovery Program Support)
Study NCT06617858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMB-05X
Description: Given by IV
Study NCT06618755 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental group : PSH (usual care) with motivational interviewing
Description: The experimental group will begin follow-up after the 1st inclusion visit, during hospitalisation for withdrawal. The first motivational interview will take place 1 to 4 days before discharge from full hospitalisation. The following 10 motivational interviews will be held 2 weeks apart and will follow a framework based on the following objectives: to create a relationship of trust and an effective and lasting therapeutic alliance from the first interview; to create personalised objectives for the user, in line with their addictive pathology; to support the user as they modify, 'fail' and 'succeed' in achieving these objectives; to encourage the emergence and maintenance of the user's desire to change.
Study NCT06680141 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality glasses
Description: control group
Study NCT06679946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vutrisiran
Description: Vutrisiran administered SC q3M
Study NCT06484400 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: Cognitive Behavioral Therapy (CBT) is a well-established psychological treatment that focuses on identifying, understanding, and changing negative thinking and behavior patterns. The intervention involves structured sessions where participants are taught strategies to alter detrimental thoughts and behaviors to improve emotional regulation and develop personal coping strategies that target solving current problems. In this study, CBT will be delivered in 12 one-hour weekly sessions conducted in person and on a one-on-one basis. This intervention is designed to reduce symptoms of depression and anxiety through cognitive restructuring and behavioral adaptations.
Study NCT06484400 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ericksonian Hypnotehrapy
Description: Ericksonian Hypnotherapy is a form of psychotherapy using clinical hypnosis and indirect suggestion to modify unconscious behaviors and thought patterns. Named after Dr. Milton H. Erickson, this therapeutic approach emphasizes adaptability and utilizes the patient's own experiences and internal resources for healing. The therapy is known for its effectiveness in addressing anxiety and depression by encouraging flexibility in perception and behavior. Like CBT, this intervention will be administered over 12 one-hour sessions, each conducted in person and tailored to the individual's unique psychological landscape.
Study NCT05104983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: The investigational drug product to be used in this study is sirolimus, provided in oral suspension.
Study NCT05104983 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study NCT06622109 — intervention group
Intervention type: BIOLOGICAL
Intervention: 20-valent Pneumococcal Conjugate Vaccine
Description: Injection in the muscle or subcutaneous , 1 dose 0.5mL
Study NCT06678659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REC-1245
Description: REC-1245 capsule 1mg, 5mg, 25mg
Study NCT05327010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BET Bromodomain Inhibitor ZEN-3694
Description: Given PO
Study NCT05327010 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy
Study NCT05327010 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT05327010 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diagnostic Imaging
Description: Undergo diagnostic imaging
Study NCT05327010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: Given PO
Study NCT06626308 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: brain functional MRI
Description: visual protocol stimulation during brain functional MRI
Study NCT06624592 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Subjects will receive standard of care anesthesia Sevoflurane, with intravenous push Dexmedetomidine
Study NCT06624592 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoflurane
Description: Subjects will receive standard of care anesthesia Isoflurane
Study NCT06672939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orforglipron
Description: Administered orally
Study NCT06672939 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study NCT06682858 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Cognitive Behavioural Therapy
Description: Participants will complete 8 group sessions of a CBT-based intervention designed to help self-regulate sensory difficulties in autistic young people
Study NCT06688214 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio Taping treatment
Description: Therapeutic KT application administered to patients in group A. The KT treatment was completed in compliance with Kase's recommended methodology for rotator cuff tendinitis/impingement. Initially, an inhibitory approach was used to apply a supraspinatus Y-strip from its insertion to its origin. The measurement of the strip's length was taken from the acromion to the scapular spine. The base of the strip was later applied to the tuberculum major while the patient was seated; the superior tale of the Y-strip was then terminated at the superomedial angle of the scapula, passing between the middle and superior fibers of the trapezius with light tension (% 15-25); the shoulder was then extended, adducted, and internally rotated with cervical contralateral bending; the final portion of the tape (2.5-5 cm) was applied painlessly.
Study NCT06688214 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Scapular Stabilization Exercises
Description: Participants in Group B engage in a twice-weekly, supervised SSE exercise program that is based on the clinical decision algorithm that has been recommended by an expert panel. The goal of scapular orientation training was to normalize the scapula's resting posture and enhance proprioception. Subsequently, three scapular control exercises were executed: a closed kinetic chain exercise known as the unilateral bench press, bilateral shoulder flexion up to 60°, and a scapular control exercise including bilateral shoulder retraction and extension in the prone position. There was no discomfort involved in performing the exercises, and each session may consist of no more than four exercises. The dosage and progressions were based on the objectives of each exercise; each exercise was performed 8-10 times with a 5- to 10-second hold in between, and there was a 30-to 1-minute rest period.
Study NCT06688279 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plyometric Exercise
Description: . The session will last for 60 minutes and 3 times per week. 5 minutes warm up with dynamic stretching and 5 minutes cool down period with static stretching and 1-minute rest period is there between each exercise and each repetition and 3-5 minute for each set (total 3 sets).~Following Plyometrics would be performed.~1. Plyo Pushup.~2. Chest Pass.~3. Overhead Throw.~4. Squat jump.~5. Plyo Step-up.~6. Cone jumps.~7. Med Ball drop.~8. Kneeling Squat jump.~9. Lateral jump over hurdle.~10. Overhead throw.~11. Under hand throws.~12. Dynamic Rotational Chest pass.~13. Overhead throw with step. Vertical jump test for lower extremity strength, 3-Hop test for lower extremity power and Star excursion balance test for dynamic balanceis performed at the start of exercise protocol and in the end i.e. Pre and post test.
Study NCT06688279 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard exercises protocol
Description: The session will last for 60 minutes and 3 times per week. Following exercises would be performed.~* Push ups.~* Sit ups.~* Lunges~* 500 m running.~* Squats Vertical jump test for lower extremity strength, 3-Hop test for lower extremity power and Star excursion balance test for dynamic balanceis performed at the start of exercise protocol and in the end i.e. Pre and post test.
Study NCT06688162 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: During the study treatment and follow-up periods, patients are to receive usual standard of care according to published guidelines for acute stroke care. It is anticipated that background care may include the use of other treatments including drugs and interventions.
Study NCT06688162 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimally Invasive Soft Channel Brain Haemorrhage Evacuation (scMIS)
Description: This technique is based on the study of hematoma anatomy, cerebral vascular anatomy, and neural fiber structure anatomy in basal ganglia hemorrhage to determine the optimal surgical (catheter insertion) path. By applying stereogeometric principles, it allows for simple yet precise localization. Through surgical steps including puncture, aspiration, liquefaction (intermittent infusion of urokinase or alteplase), and external drainage, the hematoma can be completely removed in stages over a short period. This ensures that hematoma clearance and decompression of the brain occur simultaneously, achieving a minimally invasive intracerebral hemorrhage evacuation technique with a gradual reduction in intracranial pressure.
Study NCT06623422 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: IV Infusion
Study NCT06623422 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV Infusion
Study NCT06623422 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: IV infusion
Study NCT06623422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: IV infusion
Study NCT06623422 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: IV infusion
Study NCT06623422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV infusion
Study NCT06623422 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: IV infusion
Study NCT06623422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: IV infusion
Study NCT06623422 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: IV infusion
Study NCT06623422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: IV infusion
Study NCT06623422 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: IV infusion
Study NCT06623422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: IV infusion
Study NCT06623422 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V940
Description: IM injection
Study NCT06623422 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: IM injection
Study NCT06626035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone based ERAS
Description: Children randomized to the methadone arm will receive standardized perioperative care and analgesia, including intraoperative intravenous methadone (0.1 mg/kg up to a maximum of 5 mg before incision \[pre-CPB in CS\] and 0.05 mg at the end of surgery \[after CPB in CS\]) and postoperatively, up to 4 oral doses of methadone every 12 hours before discharge as part of standardized multimodal analgesia in the hospital setting.
Study NCT06626035 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SOC non-methadone based group
Description: Children randomized to the standard-of-care arm will receive standard opioid analgesia protocol without intra- and post-operative methadone per the current site standards.
Study NCT05751226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1820237
Description: BI 1820237
Study NCT05751226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: semaglutide
Study NCT05751226 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: semaglutide
Description: semaglutide
Study NCT05751226 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05751226 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05717712 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad-TD-nsIL12
Description: After stereotactic biopsy, the Ommaya reservoir will be inserted through the biopsy channel and two injections of Ad-TD-nsIL12 will be delivered after surgery by Ommaya reservoir (with an interval of 3 days). The interval between following injections in the subsequent treatment period will be 3 weeks ±4 days. The assigned dose for each patient will be 3x10\^9vp, 1x10\^10vp or 3x10\^10 vp suspended in 1 ml NS according to cohort design.
Study NCT05751226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 456906
Description: BI 456906
Study NCT05751226 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BI 456906
Description: BI 456906
Study NCT04793984 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carragelose
Description: inhalation 3 times a day
Study NCT04793984 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: NaCl
Description: inhalation 3 times a day
Study NCT06627647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilvegostomig
Description: Administered as one intravenously (IV) on Day 1 of each 21-day cycle
Study NCT06627647 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Administered as one intravenously (IV) on Day 1 of each 21-day cycle
Study NCT06627647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered as one intravenously (IV) on Day 1 of each 21-day cycle up to 4 cycles
Study NCT06627647 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Administered as one intravenously (IV) on Day 1 of each 21-day cycle up to 4 cycles
Study NCT06627647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Administered as one intravenously (IV) on Day 1 of each 21-day cycle up to 4 cycles
Study NCT06627647 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Administered as one intravenously (IV) on Day 1 of each 21-day cycle up to 4 cycles
Study NCT06627647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Administered as one intravenously (IV) on Day 1 of each 21-day cycle
Study NCT06627647 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Administered as one intravenously (IV) on Day 1 of each 21-day cycle
Study NCT06693674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entresto Pill
Description: Patients will take a 24/26 mg dose orally, twice daily, for weeks 1 and 2, 49/51 mg orally, twice daily, for weeks 3 and 4, and 97/103 mg orally twice daily, for the remaining 48 weeks (total duration: 52 weeks).
Study NCT06693674 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients taking placebo tablets will take 1 tablet orally, twice daily
Study NCT06502977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tarlatamab
Description: IV infusion
Study NCT05215054 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gana V®
Description: Injection in the deep dermis and subcutaneous layer of the nasolabial fold on D0 (initial injection) and 1 month and a half after initial injection if necessary (optional touch-up).
Study NCT05215054 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sculptra®
Description: Injection in the deep dermis and subcutaneous layer of the nasolabial fold on D0 (initial injection) and 1 month and a half after initial injection if necessary (optional touch-up).
Study NCT05419388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7247669
Description: Participants will receive intravenous (IV) RO7247669 Q3W
Study NCT06634004 — intervention group
Intervention type: OTHER
Intervention: BOLD MRI
Description: The study will utilize the MRI diagnostic reactivity test to evaluate cerebrovascular reactivity in patients with moyamoya and healthy controls. All participants (patients and controls) receive the same diagnostic scan, and there is no cross-over, factorial, or sequential nature to the study.
Study NCT06632327 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Procedure
Description: undergo surgery
Study NCT06632327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Give cisplatin
Study NCT06632327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Give Carboplatin
Study NCT06632327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Give Pemetrexed
Study NCT06632327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Give Gemcitabine
Study NCT06632327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Give Docetaxel
Study NCT06632327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Give Vinorelbine
Study NCT06632327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Give Nivolumab
Study NCT06632327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Give Pembrolizumab
Study NCT06632327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Give Atezolizumab
Study NCT06632327 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT and/or PET/CT
Study NCT06632327 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT06632327 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study NCT06632444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Survodutide
Description: Subcutaneous injection